varnous brands ofrelated drinks in giving the history ofsensitivity. Related drinks, sharing the responsible ingredient or ingredients, would probably produce a similar response. We believe that this is the first time that cola drinks have been shown to cause symptoms of asthma.
Whatever the mechanism, the clinical relevance of an increase in airway reactivity is clear. Moreover, this method of testing for food sensitivity in asthma by looking for changes in airway reactivity may have much wider implications. Common ingredients of a normal diet might possibly cause symptoms of asthma insidiously, by increasing airway reactivity. The frequency of ingestion and lack of a direct effect on airway function would make diagnosis difficult. As we have shown that pairs of challenges with histamine performed over short intervals are highly reproducible, looking at changes in sensitivity to histamine is a simple and effective method of testing for food intolerance in asthmatic subjects.
We thank the Asthma Research Council and Napp Laboratories for financial help. 
SHORT REPORTS
Reversal of male-pattern baldness, hypertrichosis, and accelerated hair and nail growth in patients receiving benoxaprofen
Benoxaprofen is a non-steroidal anti-inflammatory drug used to relieve symptoms of rheumatoid arthritis and osteoarthrosis. Reported side effects include photosensitivity, onycholysis, urticarial rashes and pruritus, gastrointestinal ulceration and haemorrhage,l and the Stevens-Johnson syndrome. 2 We have reported the development of toxic epidermal necrolysis, leucopenia, and thrombocytopenic purpura3 in a patient after nine days' treatment with benoxaprofen. We report here on five patients who developed hypertrichosis and accelerated hair and nail growth, two of whom showed reversal of male-pattern baldness.
Case reports
Case 1-A 75-year-old man had hereditary male-pattern baldness since he was 45. At the age of 32 he had developed ankylosing spondylitis, which subsequently affected his lumbar and cervical spine and sacroiliac joints. Treatment with benoxaprofen 600 mg daily gave symptomatic relief. Within a month of starting treatment he developed photosensitivity and onycholysis, which he overcame by using sunscreens and avoiding the sun. After five months' treatment he noticed growth of hairs over an area of scalp that he previously been devoid of visible hair, and on the dorsum ofhis fingers, hands, and forearms-areas that previously had never had visible hair. He also noticed accelerated facial hair growth. The density of new hair growth on the scalp was equal to that on the areas of his scalp that were not subject to balding. Growth of scalp hair continued when he took a reduced dose of 300 mg benoxaprofen daily.
Case 2-A 39-year-old woman had had rheumatoid arthritis for several years. Benoxaprofen 600 mg daily afforded good symptomatic relief. During the first month of treatment she developed a transient pruritic, erythematous papular eruption on the dorsum of her hands; this cleared within a week.
After four months' treatment with benoxaprofen she reported an increased rate of growth of scalp hair. She then developed new hair growth on the dorsum of fingers and toes, areas that had been before hairless to the naked eye. This persisted with benoxaprofen treatment. At no time did she describe photosensitivity or develop onycholysis.
Case 3-A 70-year-old woman with longstanding osteoarthrosis was treated with benoxaprofen 600 mg daily, which afforded an improvement in her symptoms. During the first two weeks' treatment she described photosensitivity on exposure to the sun. After three weeks' treatment she developed a growth of downy blonde hair over her face (figure), limbs, and trunk. The hypertrichosis regressed soon after she stopped taking benoxaprofen.
Case 4-A 70-vear-old woman had had osteoarthrosis for about 20 years. Benoxaprofen 600 mg daily afforded good symptomatic relief. During treatment she developed photosensitivity on exposure to the sun. After one month's treatment she noticed a growth of fine blonde hairs on her face and later on her arms and legs. These areas had previously been devoid of visible hair. She continued taking benoxaprofen and the hypertrichosis persisted.
Case 5-A 45-year-old man had had hereditary male-pattern baldness since he was 40. At the age of 39 he had developed psoriatic arthropathy affecting his hands and wrists. He was treated with benoxaprofen 600 mg daily and gained considerable relief of symptoms. Within one month of starting treatment he had developed photosensitivity, which was successfully controlled by use of sunscreens. Onycholysis developed after two months' treatment. After nine months' treatment he noticed an increased growth of hair over the area of scalp previously lacking hair. He also reported an increased rate of growth of his finger nails. Treatment was reduced to 300 mg daily and the growth of new scalp hair and accelerated nail growth continued.
Comment
Hypertrichosis and accelerated hair and nail growth have not previously been described with benoxaprofen. All but one of the above patients had photosensitivity, and generally the new hair grew on sites exposed to sun. The hypertrichosis continued even when Left Left and right cheeks of woman with hypertrichosis after benoxaprofen. benoxaprofen damage was reduced; this may be due to a subclinical photosensitivity reaction, as occurs with onycholysis, which may not be associated with obvious sun sensitivity. It is not yet clear whether the hypertrichosis is simply secondary to the photosensitivity, as is seen in porphyria4 and when alopecia areata is treated with ultraviolet B or psoralen-ultraviolet A, or whether a different mechanism is entailed, as in hypertrichosis associated with minoxidil. 
